Objective: To determine the relative cost-effectiveness of insulin glulisine versus other rapid- and short acting insulins in patients with Type 2 (T2DM) diabetes applied in a Polish setting. Methods: Treatment effects were extracted from identified RCTs assessing the effects of insulin glulisine in patients with diabetes. The analysis was performed from the health care payer (Polish NHF and patient) perspective, with a time horizon of one year. Cost-utility analysis (CUA) was performed for the comparison of insulin glulisine and regular human insulin (RHI). In the absence of significant difference in clinical effectiveness, cost-minimization analysis (CMA) of insulin glulisine versus other analogs (lispro, aspart) was chosen. A range of sensitivity analyses were performed to account for uncertainty in input parameters. Results: 1) CUA: insulin glulisine was associated with increased QALYs (0.0044) resulting from reduction in nocturnal hypoglycaemia episodes, and higher costs (181 PLN per patient) compared with RHI, with the ICER of 41,385 PLN per QALY gained. The ICERs were most sensitive to the change in the number of nocturnal hypoglycaemia episodes, and 2) CMA: the cost of insulin glulisine treatment was lower than that of lispro and aspart (with the 1 year difference of 77PLN and 278PLN, respectively). Conclusion: Results of the analysis indicate that insulin glulisine is likely to represent a good value for money in the treatment of type 2 diabetes in Poland.